Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-04-14 am EDT			5-day change	1st Jan Change
246.15 ^DKK	+3.32%		+3.90%	-24.32%

Apr. 14	Health Care Up, But not by Much, on Risk Appetite - Health Care Roundup	DJ
Apr. 14	Amazon launches AI research tool to speed early-stage drug discovery	RE

NOVO NORDISK : Barclays is Neutral

Published on 02/09/2026 at 03:36 am EST

MarketScreener with dpa-AFX Analyser

NOVO NORDISK A/S

+3.32%

In a research note published by James Gordon, Barclays gives a Neutral rating to the stock. The target price is unchanged and still at DKK 360.

Latest news about Novo Nordisk A/S

Apr. 14	Health Care Up, But not by Much, on Risk Appetite - Health Care Roundup	DJ
Apr. 14	Amazon launches AI research tool to speed early-stage drug discovery	RE
Apr. 14	Novo Nordisk A/S and OpenAI Partner to Transform How Medicines Are Discovered and Delivered	CI
Apr. 14	Amazon launches AI research tool to speed early-stage drug discovery	RE
Apr. 14	European Equities Traded in the US as ADRs Rise in Tuesday Trading	MT
Apr. 14	FDA seeks additional safety data from Lilly on newly approved weight-loss pill	RE
Apr. 14	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Hopes of Long-Term US-Iran Truce	MT
Apr. 14	S&P 500 Rebound, Optimism for US-Iran Deal Move US Equity Futures Higher Pre-Bell	MT
Apr. 14	Betting on Restraint
Apr. 14	Novo Nordisk Receives UK Regulator Approval for Single-Dose 7.2mg of Wegovy	MT
Apr. 14	Wegovy Maker Novo Nordisk Strikes Deal With OpenAI to Speed Up Drug Discovery -- Update	DJ
Apr. 14	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
Apr. 14	UK Approves Novo Nordisk's Single-dose 7.2-mg Wegovy Pen	MT
Apr. 14	European Midday Briefing : Shares Rise, Oil Slips on Peace Talks Hopes	DJ
Apr. 14	UK approves new 7.2 mg single-dose injection for Wegovy	FW

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

May. 06 - Earnings release - Q1 2026

More about the company